Comparative Pharmacology
Head-to-head clinical analysis: AEROSEB HC versus HC 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROSEB HC versus HC 1.
AEROSEB-HC vs HC #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROSEB-HC (hydrocortisone/iodoquinol) exerts anti-inflammatory, antipruritic, and antifungal actions. Hydrocortisone suppresses inflammatory mediators via glucocorticoid receptor binding, while iodoquinol provides antimicrobial activity against dermatophytes and bacteria.
Unknown
AEROSEB-HC (hydrocortisone/iodoquinol) topical cream: Apply a thin film to affected area twice daily for up to 7 days. Not for ophthalmic or oral use.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
None Documented
None Documented
1.5-2 hours (terminal) after intravenous administration; prolonged in hepatic impairment.
2–4 hours (terminal); prolonged in renal impairment.
Renal (primarily as metabolites; <5% unchanged); fecal (biliary excretion of metabolites).
Renal: 90% as unchanged drug; fecal: 10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid